Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durability of Insulin Lispro Low Mix vs Glargine in T2D (IOOV)
NCT00279201Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2005
- Primary completion
- Nov 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 4, randomised, open-label trial of insulin lispro in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Glycosylated Hemoglobin (HbA1c) at 24 weeks, Duration of Time HbA1c Maintained at Goal up to 2.5 years and 1 more. Started Dec 2005; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00279201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00279201.